Tempus AI's chief legal officer Andrew Polovin sold 30,075 shares at $51.29 per share in a transaction totaling $1.5 million, according to an SEC filing. The sale was non-discretionary, executed to cover minimum statutory tax withholding obligations tied to the vesting of restricted stock units, and was conducted under a Rule 10b5-1 trading plan established on August 12, 2025. Following the disposition, Polovin retains 138,140 shares with an estimated market value of $8.5 million as of the August 19 close. Tempus AI shares have rallied about 75% since late last month, driven partly by a Moderna and Merck cancer vaccine trial hitting its endpoints, which validates the genomic sequencing technology behind Tempus's pending $1.5 billion Personalis deal. The company reported revenue up 22% to $382.5 million last quarter and its first GAAP profit.
Personalis IncPending acquisition by Tempus is validated by trial results, boosting Personalis's value.
Merck & Company Inc
Moderna Inc
Tempus AI, Inc. Class A Common StockInsider sale is non-discretionary tax withholding, not a negative signal; stock rally driven by trial validation and strong earnings.
Merck KGaA